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a  b  s  t  r  a  c  t
A  45-year-old  male  who  had  suffered  from  refractory  non-ischemic  heart  failure  treated  with  a left
ventricular  assist  device  received  heart  transplantation  in  February  2008.  He  underwent  coronary  angiog-
raphy (CAG)  and  intravascular  ultrasound  (IVUS)  at 3 months,  and  1, 2,  and 3 years  after  surgery. At
3  months,  neither  signiﬁcant  stenosis  on CAG  nor  plaque  on 3 coronary  arteries,  as  assessed  by IVUS  were
observed.  However,  focal  eccentric  plaque  on proximal  left anterior  descending  artery  has  developed  up
to  2 years,  despite  the fact  that  risk  factors  for cardiac  allograft  vasculopathy  were  well  controlled.  At
2  years,  everolimus  2.5 mg/day  was  added  to the patient’s  existing  regimen  consisting  of corticosteroids,
mycophenolate  mofetil,  and cyclosporine.  Then  mycophenolate  mofetil  was  withdrawn.  At  3 years,  con-
comitant  with  plaque  regression,  a decreased  plaque  volume  index,  enlarged  lumen  volume  index,  and
increased  minimum  lumen  area  were  observed.  We  experienced  a case  with  plaque  regression  associated
with everolimus  administration.  Further  investigations  are  needed  to explore  the  mechanism  of  plaque
regression  associated  with  everolimus,  as  well  as  to  conﬁrm  our observation  in randomized  controlled
trials  for  patients  after  heart  transplantation.
<Learning  objective:  We  experienced  a case  with  plaque  regression  associated  with  everolimus  admin-
istration.  Further  investigations  are needed  to  explore  the  mechanism  of  plaque  regression  associated
with  everolimus,  as well  as to conﬁrm  our  observation  in  randomized  controlled  trials  for  patients  after
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Cardiac allograft vasculopathy is an ongoing issue after heart
ransplantation, even though treatment regimen consisting of cal-
ineurin inhibitors, mycophenolate mofetil and glucocorticoids has
een established in patients after heart transplantation.
We report a case with plaque regression associated with
verolimis administration after heart transplantation.
A 45-year old male who had suffered from refractory non-
schemic heart failure treated with a left ventricular assist device
eceived heart transplantation in February 2008. At 3 months, and
, 2, and 3 years after surgery, he underwent coronary angiog-
aphy (CAG) (Fig. 1) and intravascular ultrasound (IVUS) (Fig. 2)
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examinations to evaluate cardiac allograft vasculopathy (CAV).
No signiﬁcant rejection episodes, as assessed by right ventricular
biopsy, were observed during the follow-up period. Although his
lipid and diabetic proﬁles were well controlled until 2 years after
heart transplantation, those parameters were worsened at 3 years,
even under statin administration, subcutaneous insulin injection,
and oral anti-diabetic drugs (Table 1 and Fig. 4). There was  no
cytomegalovirus infection during the follow-up periods.
At 3 months, neither signiﬁcant stenosis on CAG nor plaque
on 3 coronary arteries, as assessed by IVUS, were observed.
The maximum plaque thickness at 3 months on the proximal
left anterior descending (LAD) coronary artery was  0.42 mm
(Figs. 2a and 3b). At 1 year, IVUS revealed that an eccentric
focal plaque had developed with a maximum thickness of
1.06 mm at the same area in the LAD with an increased plaque
volume index (4.6 mm3/mm),  and decreased lumen volume
index (12.2 mm3/mm)  and minimum lumen area (10.9 mm2)
(Figs. 2b, 3a and 3b). At 2 years, the eccentric plaque had further
vier Ltd. All rights reserved.
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Fig. 1. Serial changes in angiogram for left coronary artery after heart transplan-
tation. No obvious stenosis on the coronary artery tree was  observed following
intracoronary injection of nitrate after heart transplantation at (a) 3 months, (b)
1  year, (c) 2 years, and (d) 3 years, even though increased plaque thickness was
detected up to 2 years, as assessed by intravascular ultrasound (IVUS). Arrows indi-
cate the site corresponding to plaque progression and regression observed by IVUS.
Fig. 2. Serial changes in plaque thickness in the proximal left anterior descending
coronary artery assessed by intravascular ultrasound (IVUS). Single (*), double (**),
and triple (***) asterisks indicate the left circumﬂex artery, ﬁrst diagonal branch,
and ﬁrst septal branch, respectively. Focusing on the site between the ﬁrst diago-
nal branch to second septal branch where plaque progression and regression took
place, we measured maximum plaque thickness, minimum lumen area as well as
lumen and plaque volume indices using Simpson’s method. (a) No obvious plaque
was  detected at 3 months. (b) At 1 year, longitudinal and cross-sectional images
showed that a focal eccentric plaque was observed in an area distal to ﬁrst diagonal
branch. (c) The plaque thickness had increased by 2 years, as shown in both the
longitudinal and cross-sectional images, with decreased lumen area. (d) Although
it  was  difﬁcult to see the ﬁrst diagonal branch due to wire artifact after transplanta-
tion, at 3 years, both the longitudinal and cross-sectional images showed decreased
plaque thickness with enlarged lumen area, which was  associated with everolimus
administration. We  note that IVUS was performed in a standard fashion using an
automated and motorized 1.0 mm/s  pullback with a commercially available imag-
ing  system with a 20-MHz IVUS catheter (Volcano Corp, Rancho Cordova, CA, USA)
at  3 months, 1 year, and 2 years after surgery, and an automated motorized 0.5 mm/s
pullback with a 40-MHz IVUS catheter (Boston Scientiﬁc Corp., Natick, MA,  USA) at
3  years after surgery, respectively.
Table 1
Laboratory data after heart transplantation.
3 months 1 year 2 years 3 years
HbA1c (%) 5.1 5.7 5.6 7.0
Total cholesterol (mg/dL) 154 193 182 219
LDL-cholesterol (mg/dL) 90 112 100 128
HDL-cholesterol (mg/dL) 36 41 49 57
Triglycerides (mg/dL) 118 190 165 134
HDL, high-density lipoprotein; LDL, low-density lipoprotein.
developed, reaching a maximum plaque thickness of 1.79 mm,
with increased plaque volume index (7.0 mm3/mm), and decreased
lumen volume index (6.9 mm3/mm),  and minimum lumen area
(5.6 mm2) (Figs. 2c, 3a, and 3b).
Subsequently, everolimus was added at an initial dose of
1.5 mg/day to the patient’s existing regimen consisting of
corticosteroids (2.5 mg/day), cyclosporine (450 mg/day), and
mycophenolate mofetil (250 mg/day). As the patient displayed
no adverse effects to everolimus in the ﬁrst week of admin-
istration, the dosage was  increased to 2.5 mg/day in order to
maintain a drug concentration of 3–8 ng/ml and mycophenolate
mofetil was  withdrawn (Fig. 4). At 3 years after transplantation
surgery, IVUS showed that the eccentric plaque in the proxi-
mal  LAD had regressed, with a maximum plaque thickness of
1.11 mm (Figs. 2d and 3b). Concomitant with plaque regression,
a decreased plaque volume index (5.1 mm3/mm),  enlarged lumen
volume index (9.0 mm3/mm), and increased minimum lumen area
(8.1 mm2) were observed (Figs. 2d and 3a). Coronary narrowing
assessed by CAG exhibited marginal progression and regression
during the follow-up period (Fig. 1).
Discussion
CAV has been reported to be a main cause of death after heart
transplantation. Previous studies have shown that numerous
recipient factors, including male sex, older age, early severe
rejection, cytomegalovirus infection, diabetes, hypertension,
hyperlipidemia, and higher body mass index, are associated with
an increased risk of CAV [1]. Although the patient did not experi-
ence any rejection episodes or viral infection, he had several risk
factors for CAV, including male sex, diabetes, and hyperlipidemia.
In addition, a plaque with a thickness of >0.5 mm had developed
within 1 year after transplantation, which is considered to be a
surrogate value of high risk for CAV [2]. A randomized clinical
trial comparing the efﬁcacy and safety between patients assigned
either to low- (1.5 mg/day) or high-dose everolimus (3.0 mg/day)
or azathioprine revealed that maximal plaque thickness 12 months
after transplantation, as assessed by IVUS, was  signiﬁcantly smaller
in the two everolimus groups than that in the azathioprine group
[3]. As the everolimus-treated group exhibited lower plaque
progression, it is possible that everolimus potentially promotes
plaque regression, resulting in a reduced risk of vasculopathy
after heart transplantation. Although the mechanism underlying
everolimus-related plaque regression after heart transplanta-
tion remains unknown, anti-immunosuppression [4] as well as
anti-inﬂammatory effects [5] may  play a role in the phenomenon.
In summary, we experienced a case with plaque regression
associated with the administration of everolimus following heart
transplantation, despite having a high risk for developing CAV. If
we encounter transplantation patients with high CAV risks, we  may
need to consider administering everolimus. Further investigations
are needed to explore the mechanism of plaque regression asso-
ciated with everolimus, as well as to conﬁrm our observation in
randomized controlled trials for patients after heart transplanta-
tion.
D. Nakatani et al. / Journal of Cardiology Cases 7 (2013) e155–e157 e157
Fig. 3. Serial changes in intravascular ultrasound parameters.
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